Rheumatology

Latest News

Using Telemedicine Interventions During COVID-19 to Expand Care Post COVID-19

January 24th 2023

The Patient-Centered Rheumatology Collaborative identified several critical areas for further intervention to improve the delivery of high-quality, patient-centered care during the COVID-19 pandemic and beyond.

A graphic with the title and health icons
Top 5 Most-Read Rheumatology Articles of 2022

January 1st 2023

picture of cannabis leaf
Cannabis Improves Quality of Life in Women With Treatment-Resistant Fibromyalgia

December 14th 2022

graphic depicting immune system
Stopping Methotrexate for 1 Week After Flu Vaccine May Work as Well as 2 Weeks

December 1st 2022

Cardiac
Early TNF Inhibitor Initiation in Ankylosing Spondylitis Linked to Increased Cardiovascular Risk

November 15th 2022

More News

heart drawing
October 16th 2020

Identifying Patients With Psoriatic Arthritis Who Need Cardiovascular Risk Factor Interventions

Laura Joszt, MA
Using the Framingham risk score to differentiate patients with psoriatic arthritis with and without coronary artery disease can underestimate cardiovascular risks in these patients.
Hand with psoriatic arthritis
October 10th 2020

Identifying the Trigger for Psoriatic Arthritis

AJMC Staff
New research may have identified the trigger that activates psoriatic arthritis in patients, according to a study published in Nature Communications.
Depressed woman crying
October 8th 2020

The Bidirectional Relationship Between Depression and Rheumatoid Arthritis

Laura Joszt, MA
Depression affects up to 17% of patients with rheumatoid arthritis, but not all patients are assessed for their mental well-being.
Is It Time to Subdivide RA Into Type 1 and Type 2 Disease?
October 2nd 2020

Is It Time to Subdivide RA Into Type 1 and Type 2 Disease?

Laura Joszt, MA
Differences in long-term outcomes in patients with rheumatoid arthritis (RA) may because RA with and without autoantibodies are actually 2 distinct conditions.
Obesity-Related Genes Are Associated With an Increased Risk of Rheumatoid Arthritis
September 25th 2020

Obesity-Related Genes Are Associated With an Increased Risk of Rheumatoid Arthritis

Laura Joszt, MA
Higher body mass index based on genes is associated with a risk of developing rheumatoid arthritis, according to an analysis of genetic data published in Arthritis & Rheumatology.
Comparing Disease Impact and Activity in Psoriatic Arthritis by Ethnic Background
September 23rd 2020

Comparing Disease Impact and Activity in Psoriatic Arthritis by Ethnic Background

Laura Joszt, MA
Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.
Transitioning From Pediatric to Adult Care Is a Vulnerable Time for Patients With Rheumatic Diseases
September 20th 2020

Transitioning From Pediatric to Adult Care Is a Vulnerable Time for Patients With Rheumatic Diseases

Laura Joszt, MA
Pediatric patients who had a referral from their pediatric rheumatologist and continued insurance coverage saw decreased delays when transitioning to an adult rheumatology clinic.
ACR Survey Reveals Patients Struggle to Maintain Access to Care During COVID-19 Pandemic
September 18th 2020

ACR Survey Reveals Patients Struggle to Maintain Access to Care During COVID-19 Pandemic

Skylar Jeremias
A survey from the American College of Rheumatology (ACR) revealed that patients with rheumatic diseases are struggling to get access to health care treatment.
Secukinumab Improves Certain PROs Equally in Patients With Early and Established PsA
September 16th 2020

Secukinumab Improves Certain PROs Equally in Patients With Early and Established PsA

Laura Joszt, MA
Both patients with early and established psoriatic arthritis (PsA) have similar improvements in general health and mental well-being after treatment with secukinumab.
Precision Medicine Could Yield Significant Cost Savings in RA Treatment
September 11th 2020

Precision Medicine Could Yield Significant Cost Savings in RA Treatment

Laura Joszt, MA
A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate response to anti–tumor necrosis factor therapies.
Healthy food
September 10th 2020

Mediterranean Diet May Prevent RA in Current or Previous Smokers

Laura Joszt, MA
The Mediterranean diet, which is known to have health benefits, may help prevent rheumatoid arthritis (RA) in current or previous smokers, according to new research published in Arthritis & Rheumatology.
The Role of Comorbidities on Disease Activity in Psoriatic Arthritis
September 3rd 2020

The Role of Comorbidities on Disease Activity in Psoriatic Arthritis

Laura Joszt, MA
Comorbidities can have an impact on the main disease domains for patients with psoriatic arthritis. For each additional comorbidity a patient has, their disease activity score increases.
Cigarette smoking
September 1st 2020

Modifiable Risk Factors Associated With Transition From Psoriasis to Psoriatic Arthritis

Laura Joszt, MA
It may be possible to modify some lifestyle and environmental factors to reduce the risk of patients transitioning from psoriasis to psoriatic arthritis.
Heart and heart beat
August 28th 2020

More CV Risk Factors Associated With Greater Disease Burden in Psoriatic Arthritis

Laura Joszt, MA
Cardiometabolic comorbidities are a considerable burden in patients with psoriatic arthritis, and patients who had a higher number of cardiovascular (CV) risk factors had greater disease activity, according to a study in Medicina.
Disease Burden in Axial Psoriatic Arthritis Differs Significantly by Gender
August 26th 2020

Disease Burden in Axial Psoriatic Arthritis Differs Significantly by Gender

Laura Joszt, MA
The burden of disease in patients with axial psoriatic arthritis (PsA) can differ significantly between genders, according to a new study published in Modern Rheumatology.
bone structure
August 21st 2020

Patients With Psoriatic Arthritis at Risk for Lower Bone Mineral Density, Osteoporosis

AJMC Staff
Patients with psoriasis and psoriatic arthritis are at a greater risk for osteopenia and osteoporosis, but the associate is the result of secondary factors, such as medication.
What We’re Reading: FDA Rejects Filgotinib; Care Barriers for LGBTQ Youth; Fauci on COVID-19 Vaccination
August 19th 2020

What We’re Reading: FDA Rejects Filgotinib; Care Barriers for LGBTQ Youth; Fauci on COVID-19 Vaccination

AJMC Staff
The FDA rejects Gilead’s new drug application for filgotinib; new survey results on mental health care access for LGBTQ youth; Anthony S. Fauci, MD, thinks a mandatory coronavirus disease 2019 (COVID-19) vaccination is unlikely.
Secukinumab Significantly Improves Signs, Symptoms of Nonradiographic Axial Spondyloarthritis
August 18th 2020

Secukinumab Significantly Improves Signs, Symptoms of Nonradiographic Axial Spondyloarthritis

Laura Joszt, MA
Secukinumab 150 mg improves signs and symptoms of patients with nonradiographic axial spondyloarthritis, according to results of the PREVENT trial published in Arthritis & Rheumatology.
Differences in the Risk of Orthopedic Surgery for Patients With RA, Psoriatic Arthritis
August 14th 2020

Differences in the Risk of Orthopedic Surgery for Patients With RA, Psoriatic Arthritis

Laura Joszt, MA
The risk of orthopedic surgery has declined for patients with rheumatoid arthritis (RA) over the course of decades, but the same trend has not occurred for patients with psoriatic arthritis.
Elderly Asian man
August 12th 2020

Fatigue Is Prevalent and Corresponds to Disease Severity in Asian Patients With Psoriatic Arthritis

Laura Joszt, MA
Most studies have evaluated PsA-associated fatigue in western populations. A new study has highlighted that PsA-associated fatigue is also prevalent in an Asian population and correlates with disease activity, impact, and chronicity.
Secukinumab Has High Retention Rate in Real-World Psoriatic Arthritis Study
August 8th 2020

Secukinumab Has High Retention Rate in Real-World Psoriatic Arthritis Study

Jared Kaltwasser
New real-world data shows 64% of patients with psoriatic arthritis who had previously been on a biologic stayed on secukinumab for the duration of the study.
Male doctor and patient
August 6th 2020

Real-World Analysis: Secukinumab Improves Psoriatic Arthritis Outcomes at 6 Months

Laura Joszt, MA
Just like in clinical trials, a real-world analysis of patients with psoriatic arthritis who were treated with secukinumab achieved minimal disease activity, as well as other improvements.
heart health
August 1st 2020

Need for Improved CVD Prevention in Patients With RA

Laura Joszt, MA
Patients with rheumatoid arthritis (RA) have a higher risk of cardiovascular disease (CVD), because inflammation plays a pivotal role in the development of CVD. However, there is a need for greater improvement of CVD risk prevention.
ACR Issues Advice on Reopening Clinics During the COVID-19 Pandemic
July 30th 2020

ACR Issues Advice on Reopening Clinics During the COVID-19 Pandemic

Laura Joszt, MA
During the coronavirus disease 2019 (COVID-19) pandemic, clinics have closed to varying degrees. As clinics look to reopen or welcome back patients after a COVID-19 infection, the American College of Rheumatology (ACR) has released advice on strategies for reopening practices as the pandemic continues.
Greater Disease Burden in Patients With Skin and Joint Symptoms for Psoriatic Arthritis
July 30th 2020

Greater Disease Burden in Patients With Skin and Joint Symptoms for Psoriatic Arthritis

Laura Joszt, MA
Patients who have both skin and joint symptoms with psoriatic arthritis have greater disease burden and worse quality of life compared with patients who have joint-only involvement.
Tocilizumab Caused Serious AEs in a Quarter of Children With Rheumatic Inflammatory Diseases
July 25th 2020

Tocilizumab Caused Serious AEs in a Quarter of Children With Rheumatic Inflammatory Diseases

Laura Joszt, MA
In children with inflammatory rheumatic diseases, tocilizumab can cause serious adverse events (AEs), with children who were younger at disease onset and at time of tocilizumab initiation especially affected.
Secukinumab Dose Escalation, Retention Rate, and Safety in Real-World Settings
July 23rd 2020

Secukinumab Dose Escalation, Retention Rate, and Safety in Real-World Settings

Laura Joszt, MA
In 2 studies of secukinumab use in real-world settings, researchers identified the usefulness of dose escalation in patients with psoriatic arthritis (PsA), as well as the safety, retention rate, and factors associated with drug survival among patients with PsA and ankylosing spondyloarthritis.
Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis
July 18th 2020

Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis

Laura Joszt, MA
Psoriatic arthritis and psoriasis have high economic burdens and the total annual costs were similar between the 2 diseases, but the combination of both yielded the highest costs, according to an abstract published at the European League Against Rheumatism annual meeting.
Identifying Factors of Delayed Diagnosis in Axial Spondyloarthritis
July 16th 2020

Identifying Factors of Delayed Diagnosis in Axial Spondyloarthritis

Laura Joszt, MA
Although early diagnosis of axial spondyloarthritis is crucial for patients to receive timely access to care and effective treatment, these patients experience a diagnostic delay of more than 7 years, on average.
Upadacitinib Proves to Be More Effective Than Methotrexate in Patients With RA
July 11th 2020

Upadacitinib Proves to Be More Effective Than Methotrexate in Patients With RA

Skylar Jeremias
Clinical trial result revealed that upadacitinib may be more effective in treating patients with rheumatoid arthritis than the gold standard of care, methotrexate.
<1
...
34567891011>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo